The study shows NSA reduces inflammation by upregulating Nrf2 pathways, but MLKL is considered the final executor of necroptosis, not a transcriptional regulator. The mechanism linking MLKL inhibition to Nrf2 activation remains unexplained and could reveal novel therapeutic targets. Gap type: unexplained_observation Source paper: Anti-inflammatory mechanism of the MLKL inhibitor necrosulfonamide in LPS- or poly(I:C)-induced neuroinflammation and necroptosis. (2025, Biochemical pharmacology, PMID:40473224)
Landscape Summary: How does MLKL inhibition upregulate Nrf2 signaling independently of its necroptosis executor function? is a 0.8 priority gap in neuroinflammation. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
How does MLKL inhibition upregulate Nrf2 signaling independently of its necroptosis executor function? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: